Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTACC-CAP: Therapeutic-Dose Heparin in Community Acquired Pneumonia
NCT05848713Phase 3Recruiting
- Sponsor
- University of Manitoba
- Start
- Oct 2023
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of heparin in community acquired pneumonia (CAP), sponsored by University of Manitoba. Started Oct 2023; status: recruiting.
02
Drugs
heparin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT05848713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05848713.